Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
National Cancer Institute (NCI)
354 participants
Mar 25, 2014
OBSERVATIONAL
Conditions
Summary
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Eligibility
Inclusion Criteria3
- European American patients with deoxyribonucleic acid (DNA) available and designated case or control
- Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
- Patients who did not develop hypertension following a full course of treatment with bevacizumab
Interventions
Correlative studies
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02610413